MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$1,577K
Free Cash flow
-$1,974K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Accounts payable and accrued exp...
Stock-based compensation
Accrued interest on revenue inte...
Others
Negative Cash Flow Breakdown
Net loss
Accounts receivable, net
Inventory
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-17,582
-30,369
-21,148
-29,973
Depreciation and amortization
114
110
128
156
Stock-based compensation
6,712
5,534
5,610
9,297
Issuance of pik interest debt
-
-
-
1,179
Accrued payment-in-kind interest on debt
0
712
4,664
-
Accrued interest on revenue interest financing liability
-
-
-
4,799
Accrued interest on revenue interest financing liability, net of payments
3,998
3,543
24,333
-
Amortization of debt discount
912
844
809
775
Loss on extinguishment of debt
0
-829
-
-
Inventory reserve
0
0
-539
0
Other
-1,283
-1,605
-865
-1,209
Prepaid expenses and other current assets
-132
-6,918
2,125
-1,392
Accounts receivable, net
16,697
2,596
22,339
4,534
Accounts payable and accrued expenses
23,398
-3,124
27,574
1,114
Accrued interest
-239
-157
68
10
Operating right-of-use assets and lease liabilities
-5
10
90
66
Inventory
3,956
-665
-2,002
-395
Other long-term assets
0
171
1,224
-
Net cash used in operating activities
-1,930
-15,647
-5,001
-14,115
Cash paid for property and equipment
44
61
87
27
Net cash used in investing activities
-44
-61
-87
-27
Proceeds from issuance of common stock from exercise of stock options
3,551
591
1,265
293
Proceeds from issuance of long-term debt, net of issuance costs
0
173,250
0
0
Repayment of long-term debt
0
229,047
-
-
Net proceeds from underwritten public offering
0
121,974
0
0
Payment of employee tax obligations related to vesting of performance stock units
-
-
-
-564
Payment of employee tax obligations related to vesting of psus and rsus
0
-128
-1,926
-
Net cash provided by financing activities
3,551
66,640
-97
-271
Net increase (decrease) in cash and cash equivalents and restricted cash
1,577
50,932
-5,185
-14,413
Cash and cash equivalents and restricted cash - beginning of period
183,765
132,833
138,018
300,125
Cash and cash equivalents and restricted cash - end of period
185,342
183,765
132,833
138,018
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common stock from...
$3,551K
(4338.75%↑ Y/Y)
Net cash provided by
financing activities
$3,551K
(4338.75%↑ Y/Y)
Net increase
(decrease) in cash and cash...
$1,577K
(101.07%↑ Y/Y)
Canceled cashflow
$1,974K
Accounts payable and
accrued expenses
$23,398K
(332.02%↑ Y/Y)
Stock-based compensation
$6,712K
(-51.40%↓ Y/Y)
Accrued interest on
revenue interest...
$3,998K
Other
-$1,283K
(59.02%↑ Y/Y)
Amortization of debt discount
$912K
(-36.22%↓ Y/Y)
Prepaid expenses and
other current assets
-$132K
(97.89%↑ Y/Y)
Depreciation and
amortization
$114K
(-67.34%↓ Y/Y)
Net cash used in
operating activities
-$1,930K
(98.69%↑ Y/Y)
Net cash used in
investing activities
-$44K
(61.74%↑ Y/Y)
Canceled cashflow
$36,549K
Net loss
-$17,582K
(89.67%↑ Y/Y)
Cash paid for
property and equipment
$44K
(-61.74%↓ Y/Y)
Accounts receivable, net
$16,697K
(34.03%↑ Y/Y)
Inventory
$3,956K
(-72.10%↓ Y/Y)
Accrued interest
-$239K
(-655.81%↓ Y/Y)
Operating right-of-use
assets and lease...
-$5K
(-107.58%↓ Y/Y)
Buy us a coffee
Phathom Pharmaceuticals, Inc. (PHAT)
Phathom Pharmaceuticals, Inc. (PHAT)